U.S. Head And Neck Cancer Therapeutics Market Size & Outlook
Related Markets
U.S. head and neck cancer therapeutics market highlights
- The U.S. head and neck cancer therapeutics market generated a revenue of USD 912.8 million in 2024 and is expected to reach USD 2,363.0 million by 2033.
- The U.S. market is expected to grow at a CAGR of 11.2% from 2025 to 2033.
- In terms of segment, immunotherapy was the largest revenue generating type in 2024.
- Immunotherapy is the most lucrative type segment registering the fastest growth during the forecast period.
Head and neck cancer therapeutics market data book summary
| Market revenue in 2024 | USD 912.8 million |
| Market revenue in 2033 | USD 2,363.0 million |
| Growth rate | 11.2% (CAGR from 2025 to 2033) |
| Largest segment | Immunotherapy |
| Fastest growing segment | Immunotherapy |
| Historical data | 2021 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Chemotherapy, Immunotherapy, Targeted Therapy |
| Key market players worldwide | Eli Lilly and Co, Sanofi SA, Merck & Co Inc, Bristol-Myers Squibb Co, AstraZeneca PLC, Takeda Pharmaceutical Co Ltd, Teva Pharmaceutical Industries Ltd, Roche Holding AG ADR, Clinigen Group |
Other key industry trends
- In terms of revenue, U.S. accounted for 40.2% of the global head and neck cancer therapeutics market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In North America, U.S. head and neck cancer therapeutics market is projected to lead the regional market in terms of revenue in 2033.
- Mexico is the fastest growing regional market in North America and is projected to reach USD 76.4 million by 2033.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Head And Neck Cancer Therapeutics Market Scope
Head And Neck Cancer Therapeutics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. head and neck cancer therapeutics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to head and neck cancer therapeutics market will help companies and investors design strategic landscapes.
Immunotherapy was the largest segment with a revenue share of 66.91% in 2024. Horizon Databook has segmented the U.S. head and neck cancer therapeutics market based on chemotherapy, immunotherapy, targeted therapy covering the revenue growth of each sub-segment from 2021 to 2033.
The U.S. is the largest head and neck cancer therapeutics market in North America. Increased incidence of head and neck cancer, recent U.S. FDA approvals for anticancer drugs, and increased awareness about cancer diagnosis and treatments are some of the factors driving the market.
The high prevalence of head and neck cancer in the country is driving the demand for advanced therapeutics. For instance, according to the American Society of Clinical Oncology (ASCO), in 2023, the number of new head and neck cancer cases in the U.S. was estimated to be 66,920, with an estimated 15,400 related deaths.
Oropharynx cancer is a type of head and neck cancer that occurs in the middle throat behind the mouth. The number of new oropharynx cancer cases was estimated to increase from 12,775 in 2020 to 13,785 by 2030, according to the International Agency for Research on Cancer (IARC).
Reasons to subscribe to U.S. head and neck cancer therapeutics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. head and neck cancer therapeutics market databook
-
Our clientele includes a mix of head and neck cancer therapeutics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. head and neck cancer therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into U.S. head and neck cancer therapeutics market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. head and neck cancer therapeutics market size, by type, 2021-2033 (US$M)
U.S. Head And Neck Cancer Therapeutics Market Outlook Share, 2024 & 2033 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
